Differences in interactions with the dopamine transporter as revealed by diminishment of Na(+) gradient and membrane potential: dopamine versus other substrates.

Differences in interactions with the dopamine transporter as revealed by diminishment of Na(+) gradient and membrane potential: dopamine versus other substrates.

Item
http://www.wikidata.org/entity/Q40381513
An N-terminal threonine mutation produces an efflux-favorable, sodium-primed conformation of the human dopamine transporterResponse variability in Attention-Deficit/Hyperactivity Disorder: a neuronal and glial energetics hypothesis.Dopamine transporter oligomerization: impact of combining protomers with differential cocaine analog binding affinitiesSKF-83566, a D1-dopamine receptor antagonist, inhibits the dopamine transporter.Dopamine Transporter Activity Is Modulated by α-Synuclein.Interaction of catechol and non-catechol substrates with externally or internally facing dopamine transporters.Differential regulation of accumbal dopamine transmission in rats following cocaine, heroin and speedball self-administrationDopamine release mediated by the dopamine transporter, facts and consequences.Characterization of [³H]CFT binding to the norepinephrine transporter suggests that binding of CFT and nisoxetine is not mutually exclusive.
P2860

Differences in interactions with the dopamine transporter as revealed by diminishment of Na(+) gradient and membrane potential: dopamine versus other substrates.

Item
http://www.wikidata.org/entity/Q40381513
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Differences in interactions wi ...... amine versus other substrates.
@en
type
label
Differences in interactions wi ...... amine versus other substrates.
@en
prefLabel
Differences in interactions wi ...... amine versus other substrates.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Differences in interactions wi ...... amine versus other substrates.
@en
P2093
P304
P31
P356
10.1016/J.NEUROPHARM.2005.07.002
P433
P478
P577
P698